This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thai, L. M. Articles by Evdokiou, A. Search for Related Content PubMed PubMed Citation Articles by Thai, L. M. Articles by Evdokiou, A.

Apo2l/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Prevents Breast Cancer–Induced Bone Destruction in a Mouse Model

¹ Department of Orthopaedics, Royal Adelaide Hospital, Adelaide University; ² Breast, Endocrine, and Surgical Oncology Unit, University of Adelaide, Royal Adelaide Hospital, Hanson Institute, Adelaide, South Australia; and ³ Bone, Joint, and Cancer Group, St. Vincent's Institute, Melbourne, Victoria, Australia

Requests for reprints: Andreas Evdokiou, Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Level 4, Bice Building, North Terrace, Adelaide 5000, South Australia, Australia. Phone: 618-8222-3107; Fax: 618-8232-3065; E-mail: andreas.evdokiou{at}adelaide.edu.au.

Breast cancer is the most common carcinoma that metastasizes to bone. To examine the efficacy of recombinant soluble Apo2 ligand (Apo2L)/tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) against breast cancer growth in bone, we established a mouse model in which MDA-MB-231 human breast cancer cells were transplanted directly into the marrow cavity of the tibiae of athymic nude mice producing osteolytic lesions in the area of injection. All vehicle-treated control animals developed large lesions that established in the marrow cavity, eroded the cortical bone, and invaded the surrounding soft tissue, as assessed by radiography, micro-computed tomography, and histology. In contrast, animals treated with recombinant soluble Apo2L/TRAIL showed significant conservation of the tibiae, with 85% reduction in osteolysis, 90% reduction in tumor burden, and no detectable soft tissue invasion. Tumor cells explanted from Apo2L/TRAIL–treated animals were significantly more resistant to the effects of Apo2L/TRAIL when compared with the cells explanted from the vehicle-treated control animals, suggesting that prolonged treatment with Apo2/TRAIL in vivo selects for a resistant phenotype. However, such resistance was readily reversed when Apo2L/TRAIL was used in combination with clinically relevant chemotherapeutic drugs, including taxol, etoposide, doxorubicin, cisplatin, or the histone deacetylase inhibitor suberoylanilide hydroxamic acid. These studies show for the first time that Apo2L/TRAIL can prevent breast cancer–induced bone destruction and highlight the potential of this ligand for the treatment of metastatic breast cancer in bone. (Cancer Res 2006; 66(10): 5363-70)

This article has been cited by other articles:

				S. Rong, J. H. Cai, and J. Andrews Cloning and apoptosis-inducing activities of canine and feline TRAIL Mol. Cancer Ther., July 1, 2008; 7(7): 2181 - 2191. [Abstract] [Full Text] [PDF]

				A. Labrinidis, V. Liapis, L. M. Thai, G. J. Atkins, C. Vincent, S. Hay, N. A. Sims, A. C. W. Zannettino, D. M. Findlay, and A. Evdokiou Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood, June 1, 2008; 111(11): 5411 - 5412. [Full Text] [PDF]

				M. Lu, A. Strohecker, F. Chen, T. Kwan, J. Bosman, V. C. Jordan, and V. L. Cryns Aspirin Sensitizes Cancer Cells to TRAIL-Induced Apoptosis by Reducing Survivin Levels Clin. Cancer Res., May 15, 2008; 14(10): 3168 - 3176. [Abstract] [Full Text] [PDF]